期刊文献+

小剂量地西他滨联合CAG方案治疗老年人急性髓系白血病及中高危骨髓增生异常综合征临床分析 被引量:10

Clinical analysis of low-dose decitabine combined with CAG regimen in treatment of elderly patients with acute myeloid leukemia and myelodysplastic syndromes patients with intermediate- or high-risk
收藏 分享 导出
摘要 目的 探讨小剂量地西他滨(DAC)治疗老年人急性髓系白血病(AML)和中高危骨髓增生异常综合征(MDS)的临床价值.方法 对19例老年AML和中高危MDS患者使用小剂量DAC(10 mg/d,连用7 d)联合CAG方案[重组粒细胞集落刺激因子(G-CSF)+阿糖胞苷(Ara-C)+阿柔比星]进行治疗;1个疗程后对疗效及不良反应进行综合评估;对患者进行生存期跟踪随访.结果 1个疗程治疗后,完全缓解8例,部分缓解7例;4个疗程治疗后,完全缓解13例(68.4%),总体反应率达到78.9%(15/19),化疗相关不良反应少.随访42个月,生存12例,中位生存时间为13.5个月(3~42个月).结论 对于中高危MDS和老年AML患者,小剂量DAC联合CAG方案有较好的疗效、较高的安全性、较低的经济负担,有利于改善患者的治疗依从性. Objective To investigate the clinical value of low-dose decitabine (DAC) in elderly patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients with intermediate-or high-risk. Methods Low-dose DAC (10 mg/d, 7 days) combined with CAG regimen were given to 19 elderly patients with AML and intermediate- or high-risk MDS patients. The efficacy and adverse reactions were evaluated after a course of treatment, and the patients were followed up for survival. Results After a course of treatment, 8 patients achieved complete remission (CR), 7 patients achieved partial remission (PR). After 4 courses of treatment, 68.4 % (13/19) of patients achieved CR, the overall response rate reached 78.9% (15/19). Fewer side effects were seen associated with chemotherapy. After 42 months of follow-up, there were 12 survival cases, the median survival time was 13.5 months (3-42 months). Conclusion Low-dose DAC combined with CAG regimen have a better efficacy, higher safety, and lower economic burden for elderly AML patients and intermediate- or high-risk MDS patients, which is beneficial to greatly improve patients' compliance.
作者 胡蓉华 孙婉玲 赵弘 郭轶先 惠吴函 万岁桂 苏力 Hu Ronghua, Sun Wanling, Zhao Hong, Guo Yixian, Hui Wuhan, Wan Suigui, Su Li (Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China)
出处 《白血病.淋巴瘤》 CAS 2017年第3期166-169,共4页 Journal of Leukemia & Lymphoma
关键词 白血病 髓样 急性 骨髓增生异常综合征 地西他滨 小剂量 CAG方案 Leukemia myelocytic acute Myelodysplastic syndromes Decitabine Low-dose CAG regimen
作者简介 通信作者:苏力,Email:suti9000@sina.cn
  • 相关文献

参考文献5

二级参考文献51

  • 1Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996. 被引量:1
  • 2张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281. 被引量:1
  • 3Saba HI. Decitabine in the treatment of myelodysplastic syn- dromes. Ther Clin Risk Manag, 2007 ;3 (5) : 807 -817. 被引量:1
  • 4Qin T, Castoro R, E1 AS, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One, 2011 ; 6 (8) : 23372 -23382. 被引量:1
  • 5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treaanent (ADOPT) trial. J Clin Oncol, 2009 ; 27 ( 23 ) : 3842 - 3848. 被引量:1
  • 6Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma,2008 ;49(4) : 690 - 695. 被引量:1
  • 7Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther, 2010;10(1) : 9 -22. 被引量:1
  • 8Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res, 2011 ; 35 (4) : 499 - 503. 被引量:1
  • 9Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood, 2011;117 (3) : 936 -941. 被引量:1
  • 10Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open- label, phase Ⅲ trial of decitabine versus patient choice, with physician advice, of either supportive care or low- dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia [J]. J Clin Oncol, 2012, 30(21 ):2670-2677. 被引量:1

共引文献128

同被引文献96

引证文献10

二级引证文献6

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈